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INTERACTION OF THE OPIATE AND
NEUROENDOCRINE SYSTEMS
PETER DEMARIA, JR. , M.D .

Opiates are known to produce various physiological effect s. Ou r und ersta nding of
these effects has been greatly increased by the discovery of the opiat e receptor an d the
endogenous opioid peptides. Recent investigation has demonstrat ed th at th ree dist inct
receptor subtypes exist ; their function is currently being activel y investiga ted .
Receptor theory holds that a drug's actions are the result of inter acti ons between
that drug and specific receptor molecules on the cell's surface. The location of the
receptors in the body and the number of drug molecules that inter act with them are
important in determining the drug's effects. Vari ations in the dru g's chemical
structure will vary its affinity for the receptor. Thi s relationship is the basis of st ructure
activity relationships (SAR), a tool used by medicinal chemists when designing drugs.
Ideally a drug will have high specificity and affinit y for one type of recept or. In the
field of psychopharmacology this ideal has not been achieved. Chlorpromazine, for
example, interacts with cholinergic and alpha-adrenergic receptors to produce anticholinergic and orthostatic hypotensive effects as well as dopamine receptors to
produce its desired antipsychotic effects. The challenge to drug designers is the
synthesis of chemicals which interact with only one receptor to provide the desired
effect.
Narcotic analgesics also have side effects. Morphine, a prot ot ypical narcot ic
analgesic, has associated hypotensive and respiratory depressant effects which are
considered disadvantageous. The narcotic antagonist naloxone has had a great impact
on the practice of medicine, and research on the opiate receptor a nd endogeno us
opiates. Clinically, it is used to reverse respiratory depression in narcotic overdoses.
Prior to naloxone, nalorphine could be used when a patient was brought into an
emergency room with narcotic-induced respiratory depression. Nalorphine, though,
has both narcotic agonist and antagonist properties. An an algesic when given alo ne, it
antagonizes the analgesic effects of morphine when given concomitantl y with
morphine. The fact that one drug could have two seemingly opposite effects prompted
researchers to investigate the possibility that more than one opiate recep tor existed. On
a tissue level, much research has been done trying to elucidate the possibility of
multiple opiate receptors. Paterson, Robsen, and Kosterlitz ( I) in a recent review
present the biochemical data indicating the existance of three distinct opiate recept ors:
mu, kappa, and delta. Evidence for three distinct opiate receptors comes from the
competitive displacement of tritiated ligands from receptors by unlabelled ligand .
Binding assays have shown maximum binding capacities (i.e. sa tura bility) of the
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different receptors by highl y selective ligan ds. Differences in distribution patterns
throughout the nervous system a nd the a bility to selectively protect receptor subtypes
from alkylation a re further evidence of three distinct opiate receptors. Studying the
role of each receptor is possible using receptor selective liga nds. Few ligands are
completely specific for one receptor a nd overlap exists. Medicinal chemists are
attempting to synthesize more specific molecules and peptides.
Armed with these findings, researchers have been curious about the function of
each receptor. For example, U 50,488, a n experimental a na lgesic drug (2) , relieves
pain but not evidentall y by binding, as morphine does, to mu recep tors, but instead to
kappa receptors. Analge sia produced by U 50,488 is reversed by naloxone, however, it
lacks the morphine-type physical dependence. And while tolerance to the analgesic
effect develop s there is no cross toleran ce to morph ine. Th ese findings with U 50,488
raise the question of mu receptor involvement in th e physical dependa nce seen with
morphine.
The mouse vas deferens preparation is felt to be a good assay of delta receptor
activity. ICI 154,129 , a selective delta receptor antagonist in the mouse vas deferen s
preparation, does not produce the mu receptor mediated Straub tail in mice. Cowen
and Gmerek (3) studied the in vivo effects of metkephamid a nd ICI 154,129 on
charcoal meal tran sit time in mice. They found that ICI 154,129 reversed the meal
transit time slowing produced by metk ephamid. Th eir work provided in vivo pharmacological evidence th at supports biochemical dat a tha t ICI 154,129 is a delta receptor
a ntagonist. The lack of interaction with levorph anol , a mu recep tor agonist, and
naloxone, a mu receptor antagon ist , in the gut is furt her evide nce that IC I 154,129 is
selective for the delta receptor.
U 50,488 and ICI 154,129 are exampl es of probes of th e opiate rece ptor that ca n
be used to better understand the function of each receptor an d the role the opiate
system plays in controlling homeosta sis, for example, opiat e's hypotensive effect.
Holaday and Faden have done substantial work in this area . Th ey administered
naloxone to rats in hypovolemic (4) a nd endotoxic (5) shock a nd found it to reverse the
hypotension, suggesting that the opiate receptor is involved in the pat hophysiology of
shock.
To better understand the mech ani sm involved, ICI 154,129 was used (6). Rats
were injected with Escherichia coli lipopolysaccharide to indu ce endotox in shock.
When the mean arterial blood pressure (MABP) fell to 20-25 mm . Hg., the anim als
were injected with saline or ICI 154,129 . MABP, pulse pressure , an d hear t rate were
monitored. Changes in these parameters were reversed by ICI 154,129 but not saline.
ICI 154,129 was ineffective in the rat tail flick test a nd the hot pla te test. These
findings indicate that antagonism of delt a receptors would help sta bilize blood pressure
in shock patients. Holaday, et aI., suggested that while naloxon e would a ntagonize
delta receptors in traumatic shock patients it would also a nta gonize mu receptor
activity thereby exacerbating the patient's pain. By using a specific delta receptor
antagonist, endogenous an algesia mediated by enkephalin s a nd endorphins at the mu
receptor would be unaffected , but the patient's blood pressure would be sta bilized.
Curtis and Lefer (7) also attempted to dissect the receptor mechanism involved in
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the hemodynamic stabilizing effect of naloxone . Using J 7747 , a de lta rece ptor
antagonist , C 7000, a delta receptor antagonist and kappa receptor ago nist , and M R
2266, a kappa receptor antagonist , they induced hem orrhagic shock in cats a nd
monitored MABP and myocardial depressant factor ( M D F) production. M DF is a
biomolecule released by cell s in shock and contributes to the dem ise of a nimals. T heir
results showed that the delta receptor a ntagonist J 7747 had a significa ntly higher final
MABP then cats treated with the delta receptor a nta gonist, kappa rece ptor ago nist C
7000, a nd that cats given the kappa receptor antagonist MR 2266 did not result in a
significantly higher MABP than untreated hemorrhaged ca ts . Sim ilar resu lts were
obtained when MDF was measured. They concluded that opia te receptors other than
the kappa receptor are involved in the pathophysiolog y of shoc k a nd tha t opia te
antagonist-ana lgesics that induce analgesia via the kappa rec eptor migh t be usefu l
therape utically. U 50,488, then, might be useful in tr auma patients whe re pa in and
shock coexist.
Case studies in the lite rature have verified the effectivene ss of naloxone in
patien ts wit h shock. T iengo (8) repo rte d an eigh t year old ad mitt ed with sept ic shock
a nd meningococca l infection in whom int ensive therapy had failed to show improvement. The patient was give n three doses of na loxone at 20- 25 minute interva ls
resulti ng in the sta bilization of blood pressure at 110/65 mm. Hg. a nd hear t rate of
l lu/rninute. Initia l values were not reported .
Wright, Phillips, an d Weller (9) presented a 33- year-old fem al e with Pseudomonas septicemia who was hypotensive (systolic, 50 mm. Hg.), oliguric, a nd refractory
to dopamine infusion . After naloxone was given, her blood pre ssure rose to 130/ 80 mm .
Hg ., her temperature returned to normal, a nd her urine out put increased to 250

rnl.Zhour.
Dirksen and coworkers reported two patients (10) . The first was a sixt ytwo-year-old fem ale with cardiogenic shock secondary to a n ex tensive myocard ia l
infarction whose blood pressure despite dobutam ine infu sion was 50 /30 mm. Hg. T he
patient was given naloxone which resulted in a blood pressure rise to 84/40 mm . Hg .
and later to 100/40 mm. Hg . A sta ble clinical condition was maintained for eleven
hours, a fter which the patient 's hemodynamic status declined a nd she di ed . The seco nd
patient followed a similar course. The authors have postulated a mech an ism of
na loxone action in pa tients with shock (11). Refer red to as the endorphin st ress sys te m,
it ties humoral neuroendocrine factors to homeostasis. They suggest st ress (e.g., severe
surgica l stress, hypovolemia , a nd various forms of shock) causes release of re leasing
factors a nd subsequen tly proo piocortin . Proopiocortin is the prohormone precu rser
which break s down to yiel d adrenocorticotropic hormone (ACTH) and bet aen dorphin . ACTH acts on the ad rena Is to release cortisol and beta-endorphin at th e
en dorphin receptor to mediate catecholam ine a nd prostaglandin rele ase. Wh ile th e
evide nce for interaction bet ween the endo rphi n sys tem a nd the catecholamines is sca nt,
an endorphin an d opiate mediated, na loxone reversi ble , inhibition of PG Ei-st imulat ed
adenylate cyclase has been de monstrated (13) . Catecholamines a nd pro staglan din s
have been shown to play an integral role in the control of microcirculation .
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Feedback plays an important role in th is model a nd helps in und erstan d ing how
exogenous corticosteroids may help in the therap y of patients in shock. Massive doses
of ste roids feed back to the hypothalamus a nd pituitary to suppress ACTH and
beta-endor ph in release. Peters, et a l., reported a series of th irteen patients with
prolonged hy potension (14). Eight of the patients were not receiving cor ticosteroid s
a nd when give n naloxone showed a 45% increase in systolic blood pr essur e. However, in
three pat ient s receiving high doses of corticosteroids a nd one patient with hypoad renocort icotropism following pituitary irradiation, na loxone failed to produ ce a pressor
response. It was felt that th e patients receivi ng high doses of corticosteroids or
suffering hypoa drenocorticotropism would have th eir ACTH a nd beta-endorphin
effectively suppressed making naloxone ad ministra tion ineffecti ve. Th ese clinical
findings support Dirksen 's proposed mec hanism .
Additional evidence for this neuroendocrine mech anism comes from experiments
wit h stress-i nduce d a na lgesia in anima ls. Exposing rat s and mice to st ressful stimuli
suc h as elect ric foot shoc k, cold wa ter swimming, centrifuga l rota tion, a nd conditioned
fear produ ces pron oun ced a na lgesia. Thi s a na lgesia is reve rsed by naloxone admi nistr ati on, which implicat es th e endoge nous opia te system in its production. Pano cka a nd
Hartmann studie d th e effec ts of bilateral ad rena lectomy (B.A .) a nd dex am eth asone on
st ress- induce d a nalgesia produced in mice by swimming (IS) . They sepa ra ted mice
into fou r groups : B.A. give n dexamethasone on the ninth postoperati ve day (POD-9);
B.A . give n sa line on POD-9; sha m adrenalectomized mice given dexa methasone on
POD-9; an d sham adre nalectomized mice give n sa line on POD-9. An algesia was tested
using hind paw flick as the end point in the mouse hot plate test. From this da ta the
a ut hors conclude that pit uita ry op iates are involved in stress-induced a na lgesia. T heir
result s support Dirk sen 's mec hanism. Both adrenalectomized group s showed an
ac centua tio n of post- st ress a nalgesia. Regardl ess of the surgica l procedure performed,
dexam eth asone a ttenua ted post-stress a na lgesia. On ce feedback to the pitu ita ry is
rem oved (e .g., adrenal ectomy) th ere is a compensatory increase in ACT H and
th er efore bet a-end orphin. Likewise, with incr eased feed back (e.g., dex am eth asone) to
th e pitui tary, AC T H a nd bet a-endor ph in a re su ppressed. An alge sia is med iat ed by the
level of bet a- end orph in a t the rece ptor.
Mo usa , M iller , a nd Co uri examined the effect of de xam eth asone a nd na loxone on
cold water swimming-ind uced a nalgesia in rats (16). In thi s study, one gro up of rat s
was pre-tr eat ed with dexam eth asone for three days. Another gr oup of rats was given
naloxone th irt y minutes pr ior to the st resso r. A third control gr oup of ra ts received an
equ ivolume dose of sa line. Pain sensitivity was tested by bot h the hot plate and tail flick
tests. Dexam eth asone significa ntly increased th e baselin e prestressor pain threshold in
the hot plate, but not th e ta il flick tests. Th e authors felt th a t the d iscrepa ncies bet ween
the tests might be expl ain ed by th e discr epan cies betw een detecta ble pa in thresholds or
involveme nt of differ ent pain pathways in the two methods. Th ey noted a simila r
phenomenon had been reported with DMSO, neurotensin, a nd enk eph alin s. Pretreat men t wit h dexam eth asone produ ced sup pression of stressor-induced a nalgesia in both
tests. 'N a loxone administered to control rats partiall y a nta gonized the stress-induced
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analgesia . The researchers concluded th at dexamethasone ma y ac t thro ugh a n indi rect
mechanism to inhibit the stress-ind uced elevation of bet a-endorphin by acting dire ctl y
on the pain-inhibiting system or via the hormones involved in tem perat ure regulation.
Data presented by different researchers indicates a clear rela tionship between
opioid and neuroendocrine system s that is probably best summa rize d by the model
proposed by Dirksen and coworkers. A better understand ing of pat hophysiological
mechanisms will no doubt emerge from further investig ati on. Th e elucidation of the
endorphin stress system's function in patients with shock is a n exa mple.
Rese arch presented in this paper demonstrates a new tie between the endogenous
opiate system and the endocrine system. This tie, in the form of proopiocort in, opens
avenues to a better understanding of stress whether induced by pain , shock, or other
factor. Perhaps one field that will greatly benefit is psychi atry. Psych iatrists are
familiar with the number of ways hum an s respond to stress (e.g. depr ession, anxi ety ,
chronic pain) . The dexamethasone suppression test (DST) currently impl ica tes a
neuroendocrine mechanism in patients suffering from depression. Depression is
frequently implicated as a cause of chronic pain. Psychi atrists believe a nxiety is a
response to an internal stressor. Both fear, a response to a real external stressor, and
anxiety produce the same symptoms. What interactions with opiate a nd neuroendocrine systems may be present in anxiety ? And what is the role of the opiate a nd
neuroendocrine systems in chronic pain? Recent research has ra ised speculation.
Romer and coworkers reported the synthesis of a n opioid benzodia zepine (17, 18).
Benzodiazepines are widely used in the treatment of a nxiety. As with opiates, a
receptor that specifica lly binds benzodiazepines has been identi fied in th e bra in. There
has also been good correlation between receptor binding affinity a nd therapeutic
effect. The molecule synthesized by Romer and coworkers, while chemicall y a
benzodiazepine, shows no affinit y for the benzod iazepin e recept or; but rather acts
selectively on the opiate kappa receptor, acting effectiv ely as a n a na lgesic a nd reversed
by naloxone. The research is still prelim inar y, but it raises que stions a bout interactions
between opiate and benzodiazepine systems and their role in pai n, stress, a nd anxi et y.
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